| Literature DB >> 30397581 |
Mohammad Johari-Ahar1,2, Jaleh Barar2,3, Pari Karami1,2, Davoud Asgari2,3, Soodabeh Davaran3, Mohammad-Reza Rashidi3.
Abstract
Introduction : Dopamine is one of the key neurotransmitters (NTs) in nature, which plays a crucial role in the mammalian central nervous system (CNS). Its selective determination in the biological fluids is an essential need in the field of biomedicine studies. Methods : In this work, an amperometric sensor was developed using Nafion-coated cadmium pentacyanonitrosylferrate (CdPCNF) modified glassy carbon (GC) electrode (Nafion|CdPCNF|GC electrode) as an electrocatalyst to detect dopamine (DA) in human serum samples. To develop this sensor, the surface of bare GC electrode was coated with the film of CdPCNF through an electropolymerization method and then the modified electrode was coated with Nafion to minimize interferences, especially those arising from the presence of anionic compounds. The electrocatalytic behavior of the modified electrodes was studied using the cyclic voltammetry and amperometry, and then the ability of the sensor for the determination of DA in synthetic and biological samples was investigated. Results : The modified electrode was showed a significant electrocatalytic activity for the oxidation of DA at pH 7.4. The limit of detection (LOD) was 0.7 µM and also no interference effects arose from ascorbic acid (AA), uric acid (UA) or the other biological NTs was observed in the DA detection using the modified Nafion|CdPCNF|GC electrode. Conclusion : In comparison with the bare electrode, the Nafion|CdPCNF|GC electrode could determine DA in the biological samples with adequate sensitivity and selectivity. Therefore, we propose that the modified electrode is utilizable as an amperometric DA sensor for the biological sample analysis.Entities:
Keywords: Amperometric sensor; Cadmium pentacyanonitrosylferrate; Dopamine; Nafion
Year: 2017 PMID: 30397581 PMCID: PMC6209831 DOI: 10.15171/bi.2018.29
Source DB: PubMed Journal: Bioimpacts ISSN: 2228-5652
Fig. 1
Fig. 2
Fig. 3
Fig. 4Comparison of our report with previous reports for DA detection
|
|
|
|
|
|
|
| Au-µA | PB-PEDOT | 4.3 | 5 – 10 | CV |
[ |
| GC electrode | HTAB-GO-MWCNT | 1.5 | 5 – 500 | A |
[ |
| GC electrode | ZrO2-GO | 9 | 9 – 237 | LSV |
[ |
| CCE | Ag | 1.4 | 6.6 – 1200 | A |
[ |
| GC electrode | AgNPs-rGO | 5.4 | 10 – 800 | LSV |
[ |
| ITO | AuNPs | 3.45 | 10 – 900 | SWV |
[ |
| GC electrode | Nafion|CdPCNF | 0.7 | 1.7 – 92.1 | A | This work |
AgNPs: Silver nanoparticles, AuNPs: Gold nanoparticles, Au-µA: Gold disk microelectrode arrays, CCE: Ceramic–graphite composite, GCE: Glassy carbon electrode, GO: Graphene oxide, HTAB: Hexadecyl trimethyl ammonium bromide, ITO: Indium tin oxide, LSV: Linear sweep voltammetry, MWCNT: multiwalled carbon nanotubes, PB: Prussian blue, PEDOT: Poly(3,4-ethylenedioxythiophene), rGO: Reduced graphene oxide, SWV: Square wave voltammetry, ZrO2: Highly loaded zirconium oxide nanoparticles, CV: cyclic voltammetry, A: amperometry,
Fig. 5
Fig. 6Determination of DA in pharmaceutical injection and human serum samples
|
|
|
|
|
|
| Pharmaceutical injection | 4.0 | 30 | 34.2±0.76** | 100.5 |
| 5.1 | 30 | 35.2±0.82 | 100.2 | |
| 3.8 | 30 | 33.1±0.67 | 97.9 | |
| 7.2 | 30 | 37.1±0.93 | 99.7 | |
| 5.4 | 30 | 35.6±0.137 | 100.5 | |
| 5.3 | 30 | 35.1±0.148 | 99.4 | |
| Serum samples | 0 | 5 | 5.1±0.13 | 102.0 |
| 0 | 10 | 9.9±0.29 | 99.0 | |
| 0 | 15 | 15.2±0.48 | 101.3 | |
| 0 | 20 | 19.8±0.38 | 99.0 |
*The unit of DA in the pharmaceutical injection and serum samples was µg/mL and µM, respectively.
** The results are expressed as 95% confidence interval for the mean of founded DA. Six replicate measurements were made on each sample.
Scheme 1
Scheme 2